Finance

Lists
AMG:ETR
Amgen Inc
367,95 €
-1,39%
(-5,20) 1D
1 հոկ, 17:35:35 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for AMG...
Open
373,15 €
High
374,50 €
Low
367,95 €
Mkt. cap
221,23 մլրդ
Avg. vol.
488,00
Volume
522,00
52-wk high
383,05 €
52-wk low
239,20 €
No. of employees
32 հզր
Open
373,15 €
High
374,50 €
Low
367,95 €
Mkt. cap
221,23 մլրդ
Avg. vol.
488,00
Volume
522,00
52-wk high
383,05 €
52-wk low
239,20 €
No. of employees
32 հզր
News stories
From web sources and news partners
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees31,5 հզր
Founded1980
HeadquartersԹաուզենդ Օուքս, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websiteamgen.com
Last report
04 օգս, 2026 թ.
Fiscal period
Q2 2026
EPS / Est. (USD)
6,29 $ / 5,62 $
+11,97%beat
Revenue / Est. (USD)
10,05 մլրդ / 9,42 մլրդ
+6,73%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
9,56 մլրդ
9,87 մլրդ
8,62 մլրդ
10,05 մլրդ
Cost of goods sold
2,74 մլրդ
2,68 մլրդ
2,50 մլրդ
2,75 մլրդ
Cost of revenue
2,74 մլրդ
2,68 մլրդ
2,50 մլրդ
2,75 մլրդ
Research and development expenses
1,90 մլրդ
2,14 մլրդ
1,72 մլրդ
1,87 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,72 մլրդ
1,95 մլրդ
1,60 մլրդ
1,74 մլրդ
Operating expense
3,55 մլրդ
4,18 մլրդ
3,21 մլրդ
3,73 մլրդ
Total operating expenses
6,29 մլրդ
6,85 մլրդ
5,70 մլրդ
6,48 մլրդ
Operating income
3,26 մլրդ
3,01 մլրդ
2,91 մլրդ
3,57 մլրդ
Other non operating income
181,00 մլն
143,00 մլն
192,00 մլն
145,00 մլն
EBT including unusual items
3,92 մլրդ
1,51 մլրդ
2,08 մլրդ
2,77 մլրդ
EBT excluding unusual items
2,72 մլրդ
2,51 մլրդ
2,37 մլրդ
3,06 մլրդ
Income tax expense
705,00 մլն
181,00 մլն
265,00 մլն
393,00 մլն
Effective tax rate
17,98%
11,96%
12,72%
14,20%
Other operating expenses
-71,00 մլն
82,00 մլն
-113,00 մլն
116,00 մլն
Net income
3,22 մլրդ
1,33 մլրդ
1,82 մլրդ
2,38 մլրդ
Net profit margin
33,65%
13,51%
21,11%
23,62%
Earnings per share
5,64
5,29
5,15
6,29
Interest and investment income
-
408,00 մլն
-
-
Interest expense
-685,00 մլն
-1,06 մլրդ
-657,00 մլն
-673,00 մլն
Net interest expenses
-685,00 մլն
-653,00 մլն
-657,00 մլն
-673,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
4,57 մլրդ
4,02 մլրդ
4,03 մլրդ
4,69 մլրդ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google Apps